Abilify first antipsychotic to be filed for depression in Japan
This article was originally published in Scrip
Executive Summary
Otsuka Pharmaceutical has applied for the approval in Japan of the atypical antipsychotic Abilify (aripiprazole) as an adjunctive therapy for major depressive disorder.